{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:40:31Z","timestamp":1790052031786,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1053\/j.seminoncol.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T20:10:29Z","timestamp":1471896629000},"page":"560-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Familial prostate cancer"],"prefix":"10.1053","volume":"43","author":[{"given":"Veda N.","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beebe-Dimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.08.001_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.2990170409","article-title":"Family history and the risk of prostate cancer","volume":"17","author":"Steinberg","year":"1990","journal-title":"Prostate"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib2","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","article-title":"Mendelian inheritance of familial prostate cancer","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/oxfordjournals.epirev.a000789","article-title":"Familial prostate cancer","volume":"23","author":"Stanford","year":"2001","journal-title":"Epidemiol Rev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","article-title":"Hereditary prostate cancer: epidemiologic and clinical features","volume":"150","author":"Carter","year":"1993","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.29075","article-title":"Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women\u2019s Health Initiative Study","volume":"121","author":"Beebe-Dimmer","year":"2015","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdr056","article-title":"Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer","volume":"23","author":"Brandt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajmg.a.20106","article-title":"Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum","volume":"121A","author":"Soravia","year":"2003","journal-title":"Am J Med Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet Med"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib10","year":"2012"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2741\/1891","article-title":"Prostate cancer epidemiology","volume":"11","author":"Hsing","year":"2006","journal-title":"Front Biosci"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib13","first-page":"1128","article-title":"Prostate cancer","author":"Platz","year":"2006"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib14","doi-asserted-by":"crossref","first-page":"s843","DOI":"10.1093\/ajcn\/86.3.843S","article-title":"Obesity, metabolic syndrome, and prostate cancer","volume":"86","author":"Hsing","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.urology.2003.11.044","article-title":"Association between Agent Orange and prostate cancer: a pilot case-control study","volume":"63","author":"Giri","year":"2004","journal-title":"Urology"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.08.001_bib16","doi-asserted-by":"crossref","first-page":"e27130","DOI":"10.1371\/journal.pone.0027130","article-title":"An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis","volume":"6","author":"Kici\u0144ski","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.genom.5.061903.180044","article-title":"Finding prostate cancer susceptibility genes","volume":"5","author":"Ostrander","year":"2004","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib18","first-page":"1115","article-title":"Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy","volume":"8","author":"Westerman","year":"2015","journal-title":"World J Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0022-5347(01)68194-1","article-title":"Familial prostate cancer: a different disease?","volume":"158","author":"Kupelian","year":"1997","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2014.07.085","article-title":"Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening","volume":"193","author":"Liss","year":"2015","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CEJ.0000000000000101","article-title":"Contribution of shared environmental factors to familial aggregation of common cancers: an adoption study in Sweden","volume":"24","author":"Sundquist","year":"2015","journal-title":"Eur J Cancer Prev"},{"issue":"11","key":"10.1053\/j.seminoncol.2016.08.001_bib22","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the Nordic Twin Study of Cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib23","first-page":"788","article-title":"Risk of breast cancer in carriers of BRCA gene mutations","volume":"337","author":"Whittemore","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1998.16.5.1969","article-title":"BRCA1 and BRCA2: from molecular genetics to clinical medicine","volume":"16","author":"Blackwood","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","article-title":"BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma","volume":"27","author":"Ferrone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/bjc.2014.428","article-title":"The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer","volume":"111","author":"Akbari","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2009.01230.x","article-title":"Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications","volume":"76","author":"Lynch","year":"2009","journal-title":"Clin Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2353\/jmoldx.2009.080142","article-title":"Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas","volume":"11","author":"Pino","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib34","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.296.12.1469","article-title":"Prediction of MLH1 and MSH2 mutations in Lynch syndrome","volume":"296","author":"Balmana","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0004.2008.01125.x","article-title":"Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations","volume":"75","author":"Barrow","year":"2009","journal-title":"Clin Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1470-2045(10)70265-5","article-title":"Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study","volume":"12","author":"Kempers","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10689-010-9388-8","article-title":"Hereditary prostate cancer as a feature of Lynch syndrome","volume":"10","author":"Bauer","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","article-title":"Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?","volume":"31","author":"Domchek","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.08.001_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Hum Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib43","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/carcin\/bgt055","article-title":"The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial","volume":"34","author":"Chen","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2013.03.007","article-title":"Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendats: a meta-analysis of 24 213 cases and 73 631 controls","volume":"640","author":"Shang","year":"2013","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10897-013-9672-5","article-title":"Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer","volume":"23","author":"Handorf","year":"2014","journal-title":"J Genet Couns"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.08.001_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1055-9965.EPI-12-1000-T","article-title":"HOXB13 G84E mutation in Finland; population-based analysis of prostate, breast and colorectal cancer risk","volume":"22","author":"Laitinen","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1053\/j.seminoncol.2016.08.001_bib47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1055-9965.EPI-12-1154","article-title":"HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease","volume":"22","author":"Witte","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.08.001_bib48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/pros.22604","article-title":"HOXB13 mutations in a population-based, case-control study of prostate cancer","volume":"73","author":"Stott-Miller","year":"2013","journal-title":"Prostate"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10689-013-9618-y","article-title":"Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer","volume":"12","author":"Alanee","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mdv004","article-title":"Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes","volume":"26","author":"Kote-Jarai","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib51","doi-asserted-by":"crossref","first-page":"e54727","DOI":"10.1371\/journal.pone.0054727","article-title":"Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E","volume":"8","author":"Macinnis","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","article-title":"A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk","volume":"65","author":"Karlsson","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/jmg.40.10.787","article-title":"A two-fold increase in BRCA mutation-related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology","volume":"40","author":"Giusti","year":"2003","journal-title":"J Med Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jnci\/djh006","article-title":"Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer","volume":"96","author":"Kirchhoff","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","article-title":"Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","volume":"15","author":"Agalliu","year":"2009","journal-title":"Clin.Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib56","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib57","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.2012.486","article-title":"An inherited NBN mutation is associated with poor prognosis prostate cancer","volume":"108","author":"Cybulski","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","article-title":"A recurrent mutation in PALB2 in Finnish cancer families","volume":"446","author":"Erkko","year":"2007","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib60","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/pros.20729","article-title":"Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer","volume":"68","author":"Tischkowitz","year":"2008","journal-title":"Prostate"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib61","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/0008-5472.CAN-03-2502","article-title":"NBS1 is a prostate cancer susceptibility gene","volume":"64","author":"Cybulski","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib62","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib63","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib64","doi-asserted-by":"crossref","first-page":"E809","DOI":"10.1111\/j.1464-410X.2012.11450.x","article-title":"Prostate cancer: germline prediction for a commonly variable malignancy","volume":"110","author":"Bambury","year":"2012","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib65","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.3094","article-title":"A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer","volume":"46","author":"Al Olama","year":"2014","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib66","unstructured":"Hindorff LA, MacArthur J, (European Bioinformatics Institute), Morales J (European Bioinformatics Institute), et al. A catalog of published genome-wide association studies. Available at: www.genome.gov\/gwastudies. Accessed December 27, 2016."},{"key":"10.1053\/j.seminoncol.2016.08.001_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib68","unstructured":"National Cancer Institute PDQ Cancer Information Summaries: Genetics. Available at: https:\/\/www.cancer.gov\/publicaitons\/pdq\/information-summaries\/genetics."},{"key":"10.1053\/j.seminoncol.2016.08.001_bib69","doi-asserted-by":"crossref","first-page":"e1004102","DOI":"10.1371\/journal.pgen.1004102","article-title":"Comprehensive functional annotation of 77 prostate cancer risk loci","volume":"10","author":"Hazelett","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib70","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1055-9965.EPI-15-0543","article-title":"Genome-wide association study of prostate cancer-specific survival","volume":"24","author":"Szulkin","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib71","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-11-1038","article-title":"Common genetic variants in prostate cancer risk prediction\u2014results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)","volume":"21","author":"Lindstrom","year":"2012","journal-title":"Cancer Epidemiol.Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib72","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng\/ml","volume":"65","author":"Nordstrom","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib73","first-page":"1","article-title":"Multigene panels in prostate cancer risk assessment","author":"Little","year":"2012","journal-title":"Evid Rep Technol Assess"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib74","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2011.40.1943","article-title":"Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers","volume":"30","author":"Park","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib75","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Genetic\/familial high-risk assessment: breast and ovarian (version 2.2016). 2012. Available at: www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf [December 27, 2015]."},{"key":"10.1053\/j.seminoncol.2016.08.001_bib76","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jclinpath-2015-202993","article-title":"Young-age prostate cancer","volume":"68","author":"Hussein","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/PAS.0000000000000090","article-title":"HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey","volume":"38","author":"Smith","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib78","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib81","unstructured":"Prostate Cancer Prevention and Early Detection. American Cancer Society Available at: www.cancer.org\/cancer\/prostatecancer. Accessed December 15, 2015."},{"key":"10.1053\/j.seminoncol.2016.08.001_bib82","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.6004\/jnccn.2015.0181","article-title":"Prostate cancer early detection, version 2.2015","volume":"13","author":"Carroll","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib83","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib84","first-page":"5","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","author":"Wiggans","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib86","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1464-410X.2011.10292.x","article-title":"Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer","volume":"109","author":"Gallagher","year":"2012","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eururo.2014.11.005","article-title":"Clinical management of prostate cancer in men with BRCA mutations","volume":"68","author":"Bratt","year":"2015","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib88","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Cancer risks in BRCA2 mutation carriers","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib89","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib90","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer Incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib91","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib92","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1011272919982","article-title":"Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland)","volume":"12","author":"Eerola","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib93","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","article-title":"BRCA mutations and risk of prostate cancer in Ashkenazi Jews","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib94","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.bjc.6603929","article-title":"Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer","volume":"97","author":"Agalliu","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib95","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","article-title":"Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis","volume":"103","author":"Edwards","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib96","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djm005","article-title":"Prostate cancer progression and survival in BRCA2 mutation carriers","volume":"99","author":"Tryggvadottir","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib97","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","article-title":"Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families","volume":"4","author":"Thorne","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib98","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2016.08.001_bib99","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bju.12522","article-title":"Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy","volume":"113","author":"Beebe-Dimmer","year":"2014","journal-title":"BJU Int"},{"issue":"5","key":"10.1053\/j.seminoncol.2016.08.001_bib100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in ment with metstatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl KJ Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T21:17:30Z","timestamp":1568323050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0093775416300604"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.08.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}